FULC · Fulcrum Therapeutics, Inc.
$3.74
+0.03 (+0.81%)
At close · Aug 14
Market Cap
$285.35M
Shares
76.30M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-06-26 | ALAN EZEKOWITZ | Director | 18,000 | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | CURTIS G OLTMANS | Officer | 3,452 | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-08 | RA Capital Healthcare Fund LP | 10% Stockholder | 4,175,139 | 2025-12-08 | BTIG, LLC |
| 2025-11-19 | ROBERT J GOULD | Director | 45,000 | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-03-08 | Greg Tourangeau | Officer | 4,884 | 2024-03-08 | Merrill Lynch, Pierce, Fenner & Smith Inc |
Showing 1–5 of 5 filings
Key facts
CIK
1680581
CUSIP
359616109
13F (30d)
152 filings
146 filers
Visit website
Investor relations